Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00193323 · ClinicalTrials.gov registry record · Phase 2
Weekly Docetaxel Versus Weekly Docetaxel/Gemcitabine in the Treatment of Non-Small Cell Lung Cancer in Elderly Patients
A Phase 2 study, sponsored by SCRI Development Innovations.
- Completed
- Registry status
- Phase 2
- Development phase
- 346
- Enrollment target
NCT00193323 is a Phase 2 study that has completed, run by SCRI Development Innovations. The registered enrollment target is 346 participants.
The verdict
NCT00193323, a Phase 2 study, has completed, sponsored by SCRI Development Innovations.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 346 participants
- Enrollment target
Study Summary
In this randomized trial, we attempt to further define optimal palliative chemotherapy for elderly patients with advanced non-small cell lung cancer by comparing single agent treatment with weekly docetaxel versus combination therapy with weekly docetaxel plus gemcitabine.
Interventions
- DRUG Docetaxel
- DRUG Gemcitabine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 346 participants |
| Start Date | 2001-08 |
| Est. Completion | 2009-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00193323
The ClinicalTrials.gov registry entry for NCT00193323 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 346 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is SCRI Development Innovations, which has 146 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Docetaxel is the first listed.
NCT00193323 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00193323 about?
NCT00193323 is a clinical study titled "Weekly Docetaxel Versus Weekly Docetaxel/Gemcitabine in the Treatment of Non-Small Cell Lung Cancer in Elderly Patients". In this randomized trial, we attempt to further define optimal palliative chemotherapy for elderly patients with advanced non-small cell lung cancer by comparing single agent treatment with weekly docetaxel versus combination therapy with weekly docetaxel plus gemcitabine.
What is the current status of trial NCT00193323?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 346 participants. The study started on 2001-08. Estimated completion is 2009-01.
What interventions are being tested in trial NCT00193323?
The interventions under investigation include: Docetaxel (DRUG), Gemcitabine (DRUG).
Who is sponsoring clinical trial NCT00193323?
This trial is sponsored by SCRI Development Innovations, which has 146 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.